Berjame, Angelita R.
HRN: 17-64-79 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/12/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/12/2023
07/17/2023
IVT
600mg
Q6
Breast CA Left
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes